S. Nair

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.

V. Palombella, Johan A. Pradeilles, Ann M. Rowley, 2016, ACS medicinal chemistry letters.

Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists.

James R. Porter, J. Sydor, M. Foley, 2008, Journal of medicinal chemistry.

Development of a Multi Kilogram-Scale, Tandem Cyclopropanation Ring-Expansion Reaction en Route to Hedgehog Antagonist IPI-926

M. Foley, S. Peluso, J. Adams, 2016 .

Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.

S. Peluso, K. West, V. Palombella, 2012, Journal of medicinal chemistry.

Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).

Jeanne A. Ferguson, J. Sydor, J. Adams, 2009, Journal of medicinal chemistry.

A Design of Experiments Approach to a Robust Final Deprotection and Reactive Crystallization of IPI-926, A Novel Hedgehog Pathway Inhibitor

Theodore A. Martinot, J. Helble, A. Côté, 2015 .

The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway

Jeanne A. Ferguson, J. Sydor, J. Adams, 2013, Xenobiotica; the fate of foreign compounds in biological systems.